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Abstract
To assess effects of epidermal growth factor (EGF) and pegylated granulocyte colony-stimulating factor (P-GCSF; pegfilgrastim) administration
on the cellular origin of renal tubular epithelium regenerating after acute kidney injury initiated by mercuric chloride (HgCl2). Female mice were
irradiated and male whole bone marrow (BM) was transplanted into them. Six weeks later recipient mice were assigned to one of eight groups:
control, P-GCSF+, EGF+, P-GCSF+EGF+, HgCl2, HgCl2+P-GCSF+, HgCl2+EGF+ and HgCl2+P-GCSF+EGF+. Following HgCl2, injection tubular
injury scores increased and serum urea nitrogen levels reached uraemia after 3 days, but EGF-treated groups were resistant to this acute kidney
injury. A four-in-one analytical technique for identification of cellular origin, tubular phenotype, basement membrane and S-phase status
revealed that BM contributed 1% of proximal tubular epithelium in undamaged kidneys and 3% after HgCl2 damage, with no effects of exoge-
nous EGF or P-GCSF. Only 0.5% proximal tubular cells were seen in S-phase in the undamaged group kidneys; this increased to 7–8% after
HgCl2 damage and to 15% after addition of EGF. Most of the regenerating tubular epithelium originated from the indigenous pool. BM contrib-
uted up to 6.6% of the proximal tubular cells in S-phase after HgCl2 damage, but only to 3.3% after additional EGF. EGF administration attenu-
ated tubular necrosis following HgCl2 damage, and the major cause of this protective effect was division of indigenous cells, whereas
BM-derived cells were less responsive. P-GCSF did not influence damage or regeneration.
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Introduction
In 1989, Humes et al. published a pioneering study describing how
infusion of epidermal growth factor (EGF) accelerated recovery from
post-ischaemic acute tubular necrosis in a rat model [1]. These
findings prompted further studies of how EGF protects against, or
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accelerates recovery from, acute renal failure in various animal mod-
els. In a model of renal ischaemia-reperfusion injury, Norman et al.
found that EGF treatment attenuated the rise in serum creatinine by
4 days after acute tubular necrosis and after 7 days, serum creati-
nine was again lower in animals receiving EGF [2]. Both of those
studies reported that infusion of EGF increased renal DNA synthesis
as visualized by tritiated thymidine autoradiography. Coimbra et al.
examined the effects of exogenous EGF during the recovery phase
of HgCl2-induced acute renal failure [3]. EGF caused greater levels of
tritiated thymidine to become incorporated into renal proximal tubule
cells, lower peak blood urea nitrogen (BUN) and serum creatinine
levels and a 4-day reduction in the time required to return to near
normal BUN and serum creatinine levels, as compared to non-EGF-
treated animals. Morin et al. also observed a similar beneficial effect
of exogenous EGF administration on the rate of tubular regeneration
in their experimental model of gentamicin nephrotoxicity [4]. Thus,
exogenous EGF is effective at promoting recovery from a variety of
acute kidney injury, even though a major source of EGF is the kidney
itself.
We proposed in 2001 that the BM contributes to renal paren-
chyma regeneration [5]. The presence of BM-derived cells was
detected in both histologically normal mouse kidneys and in human
transplanted kidneys with various causes of damage by using in
situ hybridization to detect Y chromosomes together with markers
of epithelial phenotype. The data indicate that BM stem cells con-
tribute a low percentage of cells for both normal turnover of renal
epithelia and regeneration after damage [5]. In a subsequent study
[6], female mice recipients of male whole BM were challenged with
HgCl2 and the recovery of tubular damage scores and serum urea
nitrogen (SUN) levels were assessed with or without erythropoietin
(EPO) treatment. Confocal microscopy confirmed the tubular loca-
tion of BM-derived cells and a four-in-one analytical technique (to
identifying cell origin, tubular phenotype, tubular basement mem-
branes and S-phase status) was developed to assess the relative
contribution of BM to regenerative epithelium. BM-derivation of
renal tubular epithelium increased from a baseline of 1.3–4.0%
after HgCl2. EPO increased the haematocrit, but no other renopro-
tective effects were observed. We suggest that the principle under-
lying these observations is a natural influx of cells from BM to
kidney that is stimulated by damage and assists regeneration and
repair. EPO was unable to stimulate the process in this model of
acute kidney injury, but other growth factors such as EGF may be
able to do so, and this possibility merits investigation as a method
of increasing the BM-derived population for regeneration or as a
route for cell or gene therapy to help reduce the need for kidney
transplants.
We report here a test of a strategy to increase the rate of regen-
eration of damaged kidneys in a way that could be considered for
renal therapy. The questions we asked were: does administration of
exogenous EGF improve recovery from acute tubular damage
induced by HgCl2?; does EGF act equally on resident and
BM-derived epithelium?; does a long-acting form of granulocyte
colony-stimulating factor (pegylated-GCSF) increase numbers of
BM-derived cells? and finally, is there an interaction between EGF
and P-GCSF?
Materials and methods
Recombinant human EGF
Recombinant human EGF produced in Saccharomyces cerevisiae was a
gift from Dr Jorge Berlanga-Acosta (Centre for Genetic Engineering and
Biotechnology, Havana, Cuba). The purity of the EGF was 99% based
on the results of high-pressure liquid chromatography and comprised
60% EGF1–52 (EGF protein lacking one terminal amino acid) and 40%
EGF1–51. It has bioactivity equivalent to that of full-length EGF1–53 [7, 8].
Prior to using EGF in vivo, we confirmed its bioactivity in vitro by
assessing proliferation of human skin fibroblasts in DMEM as described
[9]. The effectiveness of 0, 5, 10 and 20 ng/ml EGF in 1% foetal calf
serum (FCS) was assessed relative to the effects of 10% FCS using a
PicoGreen fluorimetric DNA assay [10].
BM adoptive transfer
All animal studies were performed under the UK Animals (Scientific Pro-
cedures) Act 1986. Before transplantation, C57BL6 female mice were
given acidified drinking water (pH 2.8–3.2 with hydrochloric acid) for
1 week to prevent Pseudomonas growth. Six-week-old female recipient
mice underwent whole body gamma-irradiation with 10 Gy in a divided
dose 3 hrs apart to ablate their BM, followed immediately by tail vein
injection of male whole BM (2 9 106 cells). Thereafter, mice were given
normal mouse feed and tap water ad libitum. There was no mortality
after BM transplantation.
Kidney damage and growth factor treatments
Six weeks after transplantation, 40 female recipient mice were randomly
assigned to one of eight groups (Table 1). In the control group, five
were injected intraperitoneally (i.p.) with vehicle (0.2 ml of PBS). In the
HgCl2 group, mice were given HgCl2 (203777, Sigma-Aldrich, Dorset,
UK) at 3 mg/kg bodyweight (bw) i.p. This dose was chosen after a pilot
study and was considered the sublethal dose enabling differentiation
between control and treatment groups [11]. Mice in the P-GCSF group
received a single subcutaneous (s.c.) injection of 25 lg of P-GCSF
(Neulasta, Amgen, Abingdon, Oxon, UK) [12, 13]. Mice in the EGF
group received 1 mg/kg bw EGF s.c. daily for 4 days. This dosage was
based on our previous experience with the effects of EGF in rodents
[14, 15].
Radioactive thymidine injection, tissue
harvesting and blood sampling
All recipient mice were killed 3 days after HgCl2 administration. This
timing was based on our previous observation that tubular damage
peaked 3 days following HgCl2 damage, followed by histological restitu-
tion at 14 days [6]. To label cells undergoing DNA synthesis tritiated
thymidine (TRK120, Amersham Biosciences, Chalfont St Giles, UK; 1
uCi/g bw i.p.) was given 1 hr prior to sacrifice. Kidneys, spleen and
long bones were removed and fixed overnight in 10% neutral buffered
formalin then transferred to 70% ethanol before being embedded in
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paraffin wax. Blood was obtained by cardiac puncture into a tube
containing the lithium salt of heparinic acid as anticoagulant (Sarstedt)
for determination of SUN using a diagnostic kit (Boehringer, Mannheim,
Germany). No animals displayed dehydration or gastrointestinal bleeding
at time of killing, either of which may cause a disproportional increment
of SUN to creatinine.
Assessing renal tissue injury
Sections (4 lm) were stained with Periodic acid–Schiff and haematoxy-
lin & eosin. Analyses were performed blinded to the sample identity. In
accordance with a procedure described previously [6, 16], the degree of
acute tubular necrosis was assessed by analysing three features of cell
injury, tubular necrosis, tubular dilatation and cast formation, by point
counting at 4009 total magnification using a Weibel 1 graticule (Pyser
SGI Ltd, Edenbridge, Kent, UK) with 50 ‘random’ points in each field.
The number of points overlying the features of interest was determined.
For each tissue section, 10 consecutive and non-overlapping fields (five
cortex and five medulla) were scored. The results were presented as a
percentage volume fraction (v/V 9 100%) for each component, where v
was the number of points recorded over the component and V was the
total number of points scored (500).
Immunohistochemical staining
Sections (4 lm) were dewaxed in xylene and endogenous peroxidases
were blocked before sections were taken through graded alcohols to water
and then to PBS [17, 18]. For antigen retrieval, sections were either sub-
jected to microwaving (700 W) in 0.01 M citrate buffer at pH 6 for 10–
20 min. or microwaving (700 W) in 2 mM ethylenediamminetetraacetic
acid solution at pH 9.0 for 10–20 min.; or incubation with bovine trypsin
[100 mg bovine trypsin (390414M; BDH Laboratory Supplies, Poole, UK),
100 mg calcium chloride, 100 ml distilled water, pH 7.8] at 37°C for 10–
15 min. After washing with PBS, sections were incubated for 35 min. with
either an antibody raised against CD45 (550539, BD Pharmingen, San
Diego, CA, USA) at a 1/20 dilution or F4/80 (MCAP497; Serotec, Oxford,
UK) at a 1/5 dilution or activated caspase 3 (AF835, R&D Systems, Abing-
don, Oxon, UK) at a 1/100 dilution. For the second layer after PBS wash-
ing, sections were incubated with either biotinylated swine anti-rabbit
(E353; Dako, Ely, UK) at a 1/500 dilution for 35 min. for rabbit antibodies,
or rabbit anti-rat biotin (A0485; Dako) at a 1/100 dilution for rat antibod-
ies. For the third layer after PBS washing, streptavidin-peroxidase (P397;
Dako) at a 1/500 dilution was applied to sections for 35 min. Slides were
developed in 3,30-diaminobenzidine (D5637; Sigma-Aldrich) plus 0.3%
hydrogen peroxide, counterstained in light haematoxylin, dehydrated and
mounted in DPX-type mount.
Four-in-one protocol
Sections were stained first for a tubular epithelial marker using lectin
histochemistry, then for the Y chromosome using in situ hybridization
(indirect method), plus for tubule basement membrane using periodic
acid–Schiff (PAS), and finally cells actively synthesizing DNA (from 3H
thymidine) were visualized by autoradiography [6].
Lectin histochemistry
Four-micrometre sections were dewaxed, their endogenous peroxidases
blocked (0.18% hydrogen peroxide in methanol) and then were taken
through graded alcohols to PBS. Biotinylated lectins were used to stain
proximal tubules [Phaseolus vulgaris leucoagglutinin (PHA-L); 1/1000;
B-1115, Vector Laboratories, Orton Southgate, Peterborough, UK].
In situ hybridization for Y chromosome
Lectin-stained sections were processed as described for direct detec-
tion, then were incubated with a peroxidase-conjugated anti-fluorescein
antibody (11 426346 910; 1/250; Roche Diagnostics Ltd, Burgess Hill,
UK) for 60 min. at room temperature, were washed, and Y signals were
developed in 3,30-diaminobenzidine (D5637; Sigma-Aldrich) plus 0.3%
hydrogen peroxide. Slides were rinsed in PBS before PAS staining.
PAS staining
Sections were oxidized with 1% aqueous periodic acid (BDH Laboratory
Supplies) for 5 min., washed in water, then were incubated in Schiff’s
reagent (BDH Laboratory Supplies) before rinsing in distilled water for
10 min. each. A light haematoxylin counterstain was followed by dehy-
dration through graded alcohols, air-drying and autoradiography.
Autoradiography
Sections were dipped in LM-1 hypercoat emulsion (RPN40; Amersham
Biosciences) at 45°C in a dark room under ‘safe light’ (902 filter) illumi-
nation. When dry, sections were stored in complete darkness at 4°C for
10–14 days then were developed, washed extensively, dehydrated,
cleared and mounted in DePeX (BDH Laboratory Supplies).
Table 1 Changes in serum urea nitrogen in female recipient mice
after kidney damage and growth factor treatments (N = 40)
Mouse group Serum urea nitrogen (mg/dl)
Control 13.58  1.04
P-GCSF+ 15.50  1.10
EGF+ 15.80  1.40
P-GCSF+EGF+ 14.98  1.27
HgCl2+ 158.10  6.27*
HgCl2+P-GCSF+ 155.52  4.56*
HgCl2+EGF+ 78.02  3.08*,†
HgCl2+P-GCSF+EGF+ 83.64  2.42*
Pegylated granulocyte colony-stimulating factor P-GCSF, epidermal
growth factor EGF, mercuric chloride HgCl2.
*P < 0.001 (compared to control group).
†P < 0.001 (compared to HgCl2 group). N = 5 per group.
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Fluorescence microscopy
Sections were examined using an Olympus BX61 epi-fluorescence
microscope with SmartCaptureX software [Digital Scientific, Cambridge,
UK (www.dsuk.biz)] to generate Red Green Blue images from multi-
channel monochrome captures.
Confocal microscopy
Laser scanning microscope system (LSM 510, Zeiss, Jena, Germany) with
C-Apochromat 1.4NA 940 water immersion objective lens was used to
produce a Z-series of sequential scans imaging four channels: 40,6-diami-
dine-20-phenylindole dihydrochloride (DAPI: band pass 420–480 nm),
fluorescein isothiocyanate (505–530 nm), red (560–615 nm) and far red
(650 nm long pass) to visualize autofluorescent materials revealing struc-
tural landmarks within tissue sections. The Y-positive cells within tubules
were easily identified by direct observation at an optical magnification of
4009. Examples of Y-positive cells were scanned at a higher magnifica-
tion with 12-bit scan dimensions of 1024 9 1024 pixels, averaged eight
times for each of 10–20 ‘optical sections’ of 0.4 lm in the Z-axis and
archived using the Zeiss LSM 510 software package.
Identification and counting of BM-derived
tubular cells
To estimate the separate contributions of indigenous kidney (female)
and BM-derived (male) cells to regeneration after renal injury, 1000
consecutively observed renal tubular epithelial cells per mouse were
scored using a light- and dark-field microscope (200x magnification;
Nikon Eclipse ME600, Tokyo, Japan). A proliferating BM-derived tubular
cell was defined by the following criteria: positive for the tubular epithe-
lial marker lectin, positive for a Y chromosome signal, observed within
the Periodic acid–Schiff-stained tubular basement membrane, and
exhibiting more than five silver grains overlying the nucleus after auto-
radiography. The 4-lm thickness of the sections enabled detection of
the Y chromosome in 71% of tubule nuclei in male control kidneys. The
counted values of Y-positive cells in the female recipients were divided
by 0.71 to reflect the total donor-derived cell population.
Statistics
Values presented in the text, tables and figures are given as means with
the standard error of mean for the number of observations. Statistical
analyses were performed with SPSS 11.0 for Mac (Chicago, IL, USA). The
data were compared and analysed using ANOVA test to compare the repli-
cate means. The null hypothesis was rejected at a P-value of 0.05 or less.
Results
Confirmation of EGF bioactivity in vitro and in vivo
Epidermal growth factor increased the proliferation of cultured der-
mal fibroblasts (Fig. S1A). The DNA fluorescence yield of 10%
FCS-treated cells (4731.50  72.32 units, ***P < 0.001) compared
with the 1% FCS-treated cells (3065.75  52.30 units) served as a
positive assay control. EGF supplementation of culture medium at
both 10 ng/ml and the 20 ng/ml in 1% FCS increased DNA synthesis
(3430.00  109.33 units and 3463.50  70.02 units respectively,
*P < 0.05). The standard curve had a linear relationship between flu-
orescence and DNA concentration with a R2 > 0.95 (Fig. S1C).
The administered EGF was bioactive in vivo, as substantiated by a
sharp increase in intestinal crypt cell proliferation (3H thymidine
incorporation) in EGF-treated mice (Fig. S1D and E) compared with
control mice (Fig. S1F and G).
Confirmation of haematopoietic reconstitution
The majority of cells in the spleen and BM were male in female recipi-
ent mice following lethal irradiation and male BM cell injection
(Fig. 1). Furthermore, some of these Y-positive cells had also incor-
porated 3H thymidine, indicating they were in S-phase (or undergoing
substantial unscheduled DNA synthesis). The level of peripheral blood
chimerism was not determined.
Induction of acute kidney injury with HgCl2
Three days after administration of HgCl2, the damaged kidneys
were macroscopically enlarged, tense and pale. Microscopically,
extensive necrosis of tubular epithelial cells was observed, with
irregular spacing and a decreased number of cell nuclei. Some
proximal tubules appeared dilated with flattened cells and attenu-
ated brush borders. Some distal tubules were also dilated and
exhibited flattened epithelial cells. Proteinaceous casts were found
in many tubules. Tubular lumens contained many sloughed epithe-
lial cells, leucocytes and cellular debris. There were apoptotic
bodies (as revealed by active caspase 3 immunostaining) in the
spleen (as positive internal control, data not shown), but not much
found in the renal parenchyma after mercuric chloride damage.
Therefore, most cell death because of mercury in this model was
as a result of necrosis not apoptosis. Consistent with the strain of
mouse used, no evidence of HgCl2-induced vasculitis was noted.
Scores for features of tissue injury (Fig. 2) were high after HgCl2
injection in contrast with the control group, which sustained no
injury (P < 0.001). Injury scores were consistent with SUN mea-
surements, and SUN was high and reached uraemic levels after
HgCl2 injection (Table 1).
Attenuation of acute kidney injury by EGF
Epidermal growth factor was renoprotective in this model as dem-
onstrated by the attenuated tubular injury scores (Fig. 2) and the
lowered SUN levels (Table 1) in EGF-treated groups (HgCl2+EGF+
and HgCl2+P-GCSF+EGF+, P < 0.001) compared to HgCl2 alone
(HgCl2+). Conversely, injected P-GCSF had no effect on these
parameters.
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Renal infiltration of leucocytes after kidney
damage and growth factor treatments
Activated leucocytes are crucial in the pathogenesis of most kidney
diseases from acute to chronic stages. In this study, levels of leuco-
cyte infiltration after HgCl2 damage and growth factor treatments
were monitored. Increased CD45-positive leucocyte recruitment to
the kidney parenchyma was noted after HgCl2 damage (Fig. 3A). Like-
wise, some limited recruitment of F4/80-positive macrophages to the
damaged kidney was noted (Fig. 3B). After damage, a significantly
increased proportion of CD45-positive cells was noted in the kidney
parenchyma after HgCl2 damage (10.46  0.44%) in comparison
with the control group (0.8  0.04%) (Fig. 3C). Moreover, mouse
groups receiving P-GCSF injections displayed increased proportions
of CD45-positive cells (12.1  0.24% for HgCl2+P-GCSF+ and
12.1  0.16% for HgCl2+P-GCSF+EGF+) compared to the HgCl2-only
group (10.46  0.44%), and the increase was statistically significant
(P < 0.001). In contrast, the proportion of CD45-positive cells in
mouse groups receiving EGF injections did not significantly differ
from their counterparts (EGF+ versus control, HgCl2+EGF+ versus
HgCl2+, P > 0.05).
Confirmation of tubular location of BM-derived
cells
To confirm the tubular location of BM-derived cells, kidney sections
were subjected to fluorescent in situ hybridization for Y chromo-
somes and then examined under both fluorescent then laser scan-
ning confocal microscopy. This allowed direct assessment that Y
chromosome signals were actually within DAPI counterstained
nuclei (Fig. 4 white arrow) rather than being artefacts (Fig. 4 black
arrow).
Cellular origin of the regenerating
tubular epithelium
To establish the cellular origin of the EGF-mediated renal regenera-
tion, sections of all kidneys were subjected to a combined ‘four-in-
one’ analysing technique. This technique was designed to identify cell
origin, tubular phenotype, reveal the tubular basement membrane and
S-phase status of individual cells after renal damage (Fig. 5). HgCl2
damage was found to increase significantly the proportion of proximal
tubular cells that were BM-derived (Fig. 6A) and in S-phase (Fig. 6B)
in all groups (P < 0.001). Regarding the cellular origin of these, the
proximal tubular cells in S-phase, most were of indigenous kidney ori-
gin (Fig. 6C, and few were derived from BM (Fig. 6D). Exogenous
EGF increased the proportion of proximal tubule cells in S-phase, par-
ticularly following acute kidney injury. P-GCSF did not affect S-phase
status alone or in combination. BM contributed ~1 in 15 of the S-
phase proximal tubular cells after HgCl2 damage, but only ~1 in 30
after additional EGF treatment.
Discussion
We observed that tubular injury scores and SUN levels were high and
reaching uraemic levels after HgCl2 injection, but as predicted EGF-
treated groups were protected from such kidney damage. BM contrib-
uted ~1% of proximal tubular epithelial cells in undamaged groups,
increasing to ~3% after HgCl2 damage. Neither EGF nor P-GCSF
A B
C D
Fig. 1 Confirmation of short-term haemat-
opoietic reconstitution. Abundant Y-posi-
tive cells (brown nuclear dot) in the
spleen (A and B) and BM (C and D) of a
female recipient mouse indicate successful
short-term haematopoietic reconstitution
(bright field, A and C). Some of these
Y-positive cells had incorporated 3H
thymidine, detected by autoradiography as
reflective silver grains under dark-field
illumination (dark field, B and D).
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AB
C
Fig. 2 Attenuation of acute kidney injury by EGF and the absence of
effects of P-GCSF. (A) Prevalence of tubular cell necrosis, (B) cast for-
mation and (C) tubular dilatation after various treatments.
A
B
C
Fig. 3 Renal infiltration of leucocytes and macrophages after kidney
damage and EGF and P-GCSF treatments. Immunohistochemistry for
(A) CD45 and (B) F4/80 reveals clusters of infiltrated leucocytes and
macrophages respectively 4 days after induction of acute kidney injury
in a female recipient of male BM. This mouse was treated with HgCl2
and EGF, but without P-GCSF treatment. (C) In mice with renal damage,
P-GCSF increased the abundance of CD45-positive cells in the kidney
(10.46  0.44% versus 0.8  0.04%, P < 0.001). EGF injections did
not affect the abundance of CD45-positive cells.
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increased the abundance of BM-derived epithelial cells. The abun-
dance of proximal tubular cells in S-phase was ~0.5% in normal kid-
ney, increasing to ~7–8% after HgCl2 damage, and to ~15% after
exogenous EGF. The majority of the regenerating tubular epithelium
was from the indigenous pool. BM contributed only to ~1 in 15 of the
proximal tubular cells in S-phase after HgCl2 damage, and to ~1 in 30
after treatment with EGF. Thus, BM-derived cells might have inherent
defects and were poorly responsive to EGF and this might place them
at a disadvantage, causing them to be lost selectively as regeneration
proceeds.
The cellular origin of newly differentiated tubular epithelium
remains controversial [6]. In several non-renal organs, local adult
Fig. 4 Four channel laser scanning confo-
cal microscopy of a kidney section from a
female mouse recipient of male bone mar-
row (BM), following mercuric chloride
HgCl2 damage and EGF treatment. A gal-
lery of images was generated from a pro-
jected Z-series to show how authentic
fluorescence in situ hybridization signals
for Y chromosomes (green) are present
within cell nuclei (blue) (white arrow),
whereas occasional green signals are arte-
factual (black arrow). The location of
some BM-derived cells within tubular
basement membranes is apparent from
tissue architecture revealed by autofluo-
rescence that has been captured in red
and far-red channels. Authentic Y signals
are always within the territory of a DAPI-
stained nucleus.
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stem cells are recognized as the cell of origin for tissue replacement,
such as haematopoietic system, skin and intestine [19]. Many studies
have suggested that exogenous BM cells, purified haematopoietic
stem cells, or cultured mesenchymal stem cells (MSCs) may infiltrate
mouse tissues and in particular, circumstances affect the course of
renal damage [20]. Results from acute kidney injury models, using
glycerol [21], ischaemia-reperfusion [22–24], cisplatin [25], folic acid
[26], HgCl2 [6] and genetically determined progressive failure in
mouse models of Alport’s syndrome [27, 28] have been reported, and
hypotheses have been generated to explain how cells from outside
the kidney might modulate regenerative processes via transdifferenti-
ation [29], cell fusion [29, 30] or cytokine release [31]. Furthermore,
it has been recently reported in a murine model of cystinosis [32] that
the therapeutic benefit of haematopoietic stem cell transplantation
was independent of renal transdifferentiation, but instead, dependent
on the level of bone marrow (BM) chimerism.
Our study tested the ability of a pegylated form of GCSF (a long-
acting covalent conjugate of the recombinant methionyl human GCSF
and monomethoxypolyethylene glycol) to mobilize BM and affect renal
regeneration following HgCl2 damage. Both GCSF and P-GCSF are fac-
tors affecting haematopoietic cells by binding to specific cell surface
receptors and thereby stimulating proliferation, differentiation, com-
mitment and end-cell functional activation [33]. Recent studies of
cellular proliferation, receptor binding and neutrophil function demon-
strate that GCSF and P-GCSF have similar mechanisms. As P-GCSF
has low renal clearance and a prolonged half-life, renal dysfunction
has no effect on the pharmacokinetics of P-GCSF; therefore, dose
adjustment in animals with renal dysfunction is unnecessary. This
growth factor is suited for experimental models of kidney failure where
renal clearance tends to vary with time. No protective effect of P-GCSF
was found in this model, which raised concerns whether the dosage
was adequate, however the proportion of CD45-positive cells
increased after HgCl2 and further increased after P-GCSF treatment.
In our study, generation of apparent ‘BM to kidney transdifferenti-
ation’ was attempted using three strategies: HgCl2, lethal irradiation
and P-GCSF. First, HgCl2 had a direct toxic effect on the S3 segment
of the proximal tubule, causing moderate to severe acute tubular
necrosis. Second, lethal irradiation enhanced the effect of the renal
injury, either as a second injury or by inhibiting regeneration of sur-
viving renal cells. Finally, P-GCSF further stimulated BM cells by
recruiting circulating leucocytes to the damaged kidney. However, the
abundance of BM-derived tubular cells was not affected by P-GCSF
and this contrasts with the enhancement by GCSF of engraftment by
BM-derived cells reported in murine models of liver disease [34].
Togel et al. examined whether increased circulation of CD34-posi-
tive cells, induced by their mobilization from the BM, would improve
renal function and outcome in mice with ischaemic acute renal failure
[35]. Boosting peripheral CD34-positive cells (after cyclophosphamide
and GCSF treatment) failed to exert any renoprotective effects but
rather was associated with greatly increased severity of renal failure as
well as increased mortality. Because identical ischaemic injury in neu-
tropenic mice reduced renal insufficiency and significantly reduced
mortality, it was deduced that adverse effects of pharmacological
CD34-positive cells mobilization were primarily mediated by the con-
comitant induction of marked granulocytosis. Thus, high numbers of
A
B
C
Fig. 5 Detection of bone marrow (BM)-derived tubular epithelium in
S-phase using the ‘four-in-one’ technique. (A) Control tissues stained
with biotinylated Phaseolus vulgaris leucoagglutinin lectin (red) and
indirect in situ hybridization for Y chromosomes (brown) showing
co-localization of staining in the proximal tubule in male proximal
tubules and no Y signals in female tissue. (B and C) Regions of kid-
ney from female recipients of male BM that received HgCl2 damage
and EGF treatment stained using the four-in-one protocol; these
examples show BM-derived proximal tubule epithelial cells either (B)
with or (C) without incorporation of 3H thymidine that reveals
the BM-derived epithelial cell to be in S-phase. The dark-field pan-
els allow autoradiographic silver grains to be seen as bright white
dots.
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activated granulocytes apparently mask the potential renoprotective
and positive survival effects of pluripotent haematopoietic stem cells,
mediated by both their injurious renal and systemic actions. Similarly,
there was no renoprotective effect of P-GCSF in this study.
Despite attenuation of renal damage, the percentage of S-phase
proximal tubule cells in EGF rescued mice kidneys was only 16%. The
reason was unclear, but possibly related to effect of whole body
gamma-irradiation. In an earlier study [36], it was found that 2 days
after ischaemia-reperfusion injury, 50.5% of outer medullary epithelial
cells co-express Ki67 and red fluorescent protein, indicating that dif-
ferentiated epithelial cells that survived injury undergo proliferative
expansion. After repair was complete, 66.9% of epithelial cells had
incorporated bromodeoxyuridine, compared to only 3.5% of cells in
the uninjured kidney [36].
It has been proposed [37] that EGF could be used for ex vivo
expansion of BM-derived MSCs, although species specific effects of
A B
DC
Fig. 6 The effects of acute kidney injury, EGF and P-GCSF on the proportion of proximal tubular cell proliferation of BM-origin and on S-Phase sta-
tus. (A) Acute kidney injury increased the proportion of proximal tubule cells derived from BM irrespective of treatment with EGF and/or P-GCSF,
thus scoring of these cells was not affected by the influx of CD45 cells after P-GCSF. (B) The proportion of proximal tubule cells in S-phase was
increased by acute kidney injury and EGF synergistically, whereas P-GCSF was without effect. (C) Indigenous proximal tubule cells responded to
acute kidney injury and more so in combination with EGF, whereas P-GCSF had no effect on S-phase status. (D) A small but statistically significant
increase occurred in the proportion of exogenous (BM-derived) proximal tubule cells in S-phase, with no effect of EGF or P-GCSF. Differences from
corresponding control groups: ***P < 0.001. Means  SEM, n = 5.
ª 2014 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
471
J. Cell. Mol. Med. Vol 19, No 2, 2015
EGF are reported: EGF stimulated the motility of rat and immortalized
human BM-derived MSCs, but proliferation was inducible only in
immortalized human BM-derived MSCs and not rat BM-derived
MSCs. EGF caused robust phosphorylation of extracellular signal-reg-
ulated protein kinase (ERK) and protein kinase B/akt, but only minimal
phosphorylation of EGFR and phospholipase C-gamma in rat BM-
derived MSCs, whereas in the human BM-derived MSCs, these inter-
mediaries were all strongly activated. EGF also induced robust ERK
activation in primary porcine MSCs. EGF pre-treatment or co-treat-
ment did not interfere with secondarily induced differentiation of
either type of BM-MSC along adipogenic or osteogenic lineage, or
rescue MSC from apoptosis induced by serum-deprivation. Taken
together, these findings suggest that EGF may not be universally sui-
ted for ex vivo expansion and direction of BM-derived MSCs [37].
A potential concern over the use of EGF for driving renal regenera-
tion is whether the long-term activation of EGF receptors on kidney
cells would increase the chance of renal cell carcinoma [38]. Many
studies have documented increased overexpression of the EGF recep-
tor (c-erbB1) and its ligands EGF and transforming growth factor-
alpha in renal cell carcinoma [39]. Furthermore, autocrine and
paracrine signalling loops are associated with development and
progression of renal cell carcinoma metastasis [40]. Therefore, although
strategies that activate EGF/EGF receptor may accelerate renal recovery,
they may produce untoward proliferative effects if the activation is not
carefully regulated. Preliminary data [41] from studies by our team in
multiple intestinal neoplasia (Min) mice, that exhibit polyposis
because of a genetic defect in the Apc gene, suggest that administra-
tion of EGF does not increase the number of polyps or degree of dys-
plasia, but does cause a 40% increase in polyp size in the proximal
intestine specifically (P < 0.02). The remainder of the small intestine
or colon, however, exhibits no such increase [41]. No polyps were
found in control mice given EGF and EGF did not initiate polyp forma-
tion in control or Min mice. However, as polyp size is an important
determinant of subsequent risk for malignant change in human colon
cancer, further studies are warranted of the effects of EGF.
Conclusion
In summary, we confirm that treatment with exogenous EGF attenu-
ated tubular necrosis following HgCl2 damage, and by comparing our
data from a non-transplant setting (protective effect of EGF after
HgCl2 damage) to a transplant model (following sex-mismatched BM
transplantation), we have been able to assess the relative contribution
of indigenous versus BM-derived cells to renal regeneration after
damage. The action of EGF appears primarily to be to drive division of
indigenous cells, whereas BM-derived cells – whether generated by
fusion or not – were less responsive. P-GSCF had no renoprotective
effects alone or in combination with EGF.
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